| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. |
|
Medicine details |
|
| Medicine name | dabigatran etexilate (Pradaxa®) |
| Formulation | capsule |
| Reference number | 443 |
| Indication | Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more of the following risk factors: previous stroke, transient ischemic attack, or systemic embolism (SEE); left ventricular ejection fraction < 40%; symptomatic heart failure, ≥ New York Heart Association (NYHA) Class 2; age ≥ 75 years; age ≥ 65 years associated with one of the following: diabetes mellitus, coronary artery disease, or hypertension |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/06/2011 |
| NICE guidance | |